

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

•				
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/997,099	11/29/2001	Mary Mowrey-McKee	LP/V-31594/A	3645
31781 7590 10/09/2007 CIBA VISION CORPORATION		EXAMINER		
PATENT DEP	ARTMENT	·	YU, GINA C	
11460 JOHNS CREEK PARKWAY DULUTH, GA 30097-1556			ART UNIT	PAPER NUMBER
<i>D</i> 020111, 011	30077 1330		1617	<del></del>
			MAIL DATE	DELIVERY MODE
			10/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	09/997,099	MOWREY-MCKEE ET AL.	
Office Action Summary	Examiner	Art Unit	
	Gina C. Yu	1617	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on 9/21/2      This action is <b>FINAL</b> . 2b) ☑ This      Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4)  Claim(s) 10-18 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5)  Claim(s) is/are allowed. 6)  Claim(s) 10-18 is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) are subject to restriction and/or	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated any not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate	

Application/Control Number: 09/997,099

Art Unit: 1617

#### **DETAILED ACTION**

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 21, 2007 has been entered.

## Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 10-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith (US 7067547 B1).

Smith teaches an aqueous contact lens solution comprising an effective amount of preserving agent and buffer, wherein the preserving agent is polyhexamethylene biguanimide and alexidine salts, and the buffer is Bis Tris Propane buffer. See col. 1, lines 23 – 33; Claim 2. The reference also indicates that surfactants (poloxamines and poloxamer), chelating agents (edentate disodium dihydrate), tonicity agent (sodium chloride), and a cellulosic viscosity modifying agent are commonly added in marketed products. See Example.

While there is no specific formulation comprising applicants' microbicide and Bis

Tris propane buffer, it is viewed that one of ordinary skill in the art at the time of the

present invention would have obviously made the combination according to the

Application/Control Number: 09/997,099

Art Unit: 1617

teachings of the Smith reference in expectation of successfully making an aqueous contact lens solution.

Bis Tris Propane of the prior art is said to be "1, 2-bis-ris(hydroxymethyl)methylamino)propane". It is viewed that applicants' bis tris propane is not *patentably distinct* form the prior art bis tris propane., which is position isomer of and chemically similar to, the bis tis propane of the present invention, 1,3-bis (tris(hydroxymethyl)methylamino)propane. Thus a skilled artisan would have had a reasonable expectation that using 1,3-bis (tris(hydroxymethyl)methylamino)propane as suggested by Smith would have produced similar disinfectant results as recited by the present claims.

## Response to Arguments

Applicant's arguments with respect to claims 10-18 have been considered but are moot in view of the new ground(s) of rejection.

Applicants assert that the prior art fails to teach the claimed disinfectant property as recited by the present invention. However, as discussed above, Smith already teaches using "1, 2-bis-ris(hydroxymethyl)methylamino)propane" bis-tris buffer in combination with the same polyhexamethylene biguanimide antimicrobial agent to make a contact lens solution. The fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See *Ex parte Obiaya*, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). In this case, burden is on applicants to show that applicant's composition produces unexpected and nonobvious results in comparison to the closest prior art.

Art Unit: 1617

#### Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gina C. Yu whose telephone number is 571-272-8605. The examiner can normally be reached on Monday through Friday, from 9:00 AM until 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Gina Yu Gina Yu Patent Examiner